Aromatase inhibitors: Possible future applications

Simple item page
dc.contributor.authorKaraer Ö.
dc.contributor.authorOruç S.
dc.contributor.authorKoyuncu F.M.
dc.date.accessioned2024-07-22T08:24:16Z
dc.date.available2024-07-22T08:24:16Z
dc.date.issued2004
dc.description.abstractIn premenopausal women ovaries are the major sites of estrogen production, while in postmenopausal women estrogen is produced by aromatization of ovarian and adrenal androgens in extragonadal sites, mostly in adipose tissue. Aromatase is a cytochrome P450 hemoprotein-containing enzyme complex that catalyzes the rate-limiting step in the conversion of androstenedione and testosterone to estrone and estradiol (E2). Aromatase inhibitors (AIs) have been developed primarily for use in either natural or surgical postmenopausal patients. In premenopausal women, the ovary can overcome the estrogen blockade by reflex increments of luteinizing hormone (LH) and follicle stimulating hormone (FSH), so AIs must be combined with a gonadotropin releasing hormone (GnRH) agonist to prevent the reflex LH and FSH increments. In advanced hormone-dependent breast cancer treatment, AIs have been shown to be superior to tamoxifen. Preliminary evidence also suggests superiority in the adjuvant, neoadjuvant settings and also for breast cancer prevention. AIs have been used in infertility and can increase ovulation rate. Reducing FSH dose, estrogen levels, improving response to FSH, implantation rates, and developing multiple follicles that can be used in in vitro maturation procedures are potential areas that AIs might be used in in assisted reproductive technologies (ART), besides simple ovulation induction. AIs are reported to be successful in treatment of endometriosis, an estrogen-dependent process. The use of AIs in gynecomastia, puberte precox, leiomyoma uteri, some estrogen-dependent cancers (ovarian), endometrial cancer and male infertility are reported; some of the results are promising but more clinical trials are needed. AIs are predicted to become the gold standard in the treatment of estrogen-dependent diseases in reproductive medicine in the near future. © Acta Obstet Gynecol Scand 83 2004.
dc.identifier.DOI-ID10.1111/j.0001-6349.2004.00562.x
dc.identifier.issn00016349
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19900
dc.language.isoEnglish
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAromatase Inhibitors
dc.subjectBreast Neoplasms
dc.subjectEnzyme Inhibitors
dc.subjectFemale
dc.subjectHumans
dc.subjectNeoplasms, Hormone-Dependent
dc.subjectaminoglutethimide
dc.subjectanastrozole
dc.subjectandrostenedione
dc.subjectapolipoprotein B
dc.subjectaromatase
dc.subjectaromatase inhibitor
dc.subjectclomifene citrate
dc.subjectestradiol
dc.subjectestrogen
dc.subjectestrone
dc.subjectexemestane
dc.subjectfadrozole
dc.subjectfollitropin
dc.subjectformestane
dc.subjectgonadorelin agonist
dc.subjectgonadorelin derivative
dc.subjectletrozole
dc.subjectlow density lipoprotein cholesterol
dc.subjectluteinizing hormone
dc.subjectmegestrol acetate
dc.subjectraloxifene
dc.subjectselective estrogen receptor modulator
dc.subjecttamoxifen
dc.subjecttestolactone
dc.subjecttestosterone
dc.subjectvorozole
dc.subjectzoledronic acid
dc.subjectAlbright syndrome
dc.subjectaromatization
dc.subjectatherosclerosis
dc.subjectbreast cancer
dc.subjectcancer adjuvant therapy
dc.subjectcancer hormone therapy
dc.subjectcancer prevention
dc.subjectclinical trial
dc.subjectdiarrhea
dc.subjectdrug classification
dc.subjectdrug dose reduction
dc.subjectdrug eruption
dc.subjectdrug indication
dc.subjectdrug mechanism
dc.subjectdrug megadose
dc.subjectdrug response
dc.subjectdrug structure
dc.subjectdyspnea
dc.subjectendometriosis
dc.subjectendometrium cancer
dc.subjectenzyme activity
dc.subjectestrogen blood level
dc.subjectestrogen synthesis
dc.subjectestrogen therapy
dc.subjectfemale infertility
dc.subjectfertilization in vitro
dc.subjectfever
dc.subjectfirst pass effect
dc.subjectgynecomastia
dc.subjectheadache
dc.subjecthormone release
dc.subjecthot flush
dc.subjecthuman
dc.subjecthyperlipoproteinemia
dc.subjectinfertility therapy
dc.subjectinjection site
dc.subjectlethargy
dc.subjectmale infertility
dc.subjectmenopausal syndrome
dc.subjectnausea
dc.subjectnidation
dc.subjectnonhuman
dc.subjectovary cancer
dc.subjectovary cyst
dc.subjectovulation induction
dc.subjectpostmenopause
dc.subjectprecocious puberty
dc.subjectpriority journal
dc.subjectreview
dc.subjectsecondary osteoporosis
dc.subjectside effect
dc.subjectthromboembolism
dc.subjectuterus myoma
dc.subjectvagina bleeding
dc.subjectweight gain
dc.titleAromatase inhibitors: Possible future applications
dc.typeReview

Files

Collections

Scopus Koleksiyonu